Industry Insights: Bioconjugate momentum builds with wave of regulatory approvals, clinical advances, and conference data disclosures

March through mid-April saw sustained clinical momentum across the bioconjugate landscape, with a high volume of trial initiations, regulatory milestones, and data readouts spanning a broad range of ADC formats and emerging conjugate modalities. First-in-human and early-phase studies were initiated for multiple programs, including dual-payload ADCs from Callio Therapeutics and Adcytherix, GlycoNex’s glycan-targeting ADC in gastrointestinal cancers, and Samsung Bioepis’ Nectin-4-targeting SBE303. Bispecific and next-generation ADCs continued to advance, with Alphamab Oncology dosing the first patient in a Phase 3 study of its TROP2/HER3 bispecific ADC JSKN016 in triple-negative breast cancer. Beyond oncology, novel conjugate modalities gained clinical traction, with ArkBio initiating a Phase 1 trial of an antiviral Fc conjugate for influenza and OKYO Pharma reporting Phase 2a data for a lipid-conjugated peptide agonist in neuropathic corneal pain. Regulatory activity was particularly active, with trastuzumab deruxtecan receiving three notable approvals or label updates in Japan and China, alongside EMA validation of enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer and Fast Track designations for ZW191 and SIM0505 in platinum-resistant ovarian cancer. Late-stage clinical data presented at the Society of Gynecologic Oncology Annual Meeting highlighted increasingly competitive efficacy profiles, with GSK’s mocertatug rezetecan, AbbVie’s mirvetuximab soravtansine-gynx, and BioNTech and DualityBio’s trastuzumab pamirtecan all reporting encouraging response rates across gynecologic cancer indications. Dealmaking activity was headlined by Gilead Sciences’ agreement to acquire Tubulis for up to $5 billion and Eli Lilly’s acquisition of CrossBridge Bio, while financing rounds for Adcendo, Sidewinder Therapeutics, Stipple Bio, and Oncomatryx underscored continued investor confidence in next-generation ADC platforms. A notable cluster of AI-driven biomarker collaborations also emerged, with Daiichi Sankyo entering separate agreements with Tempus AI, Imagene AI, and 4D Path to advance patient stratification across its ADC portfolio. The AACR Annual Meeting 2026 served as a focal point for preclinical platform showcasing, with more than 20 companies presenting data spanning dual-payload designs, masked ADCs, degrader-antibody conjugates, and novel linker-payload technologies.